A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer
OBJECTIVES: I. Evaluate the clinical effectiveness of oral perillyl alcohol given to
patients with androgen independent metastatic prostate cancer. II. Assess the toxicity of
this treatment in these patients.
OUTLINE: Patients receive oral perillyl alcohol 4 times a day for 4 weeks. Patients continue
treatment in the absence of severe toxicity and disease progression. Patients are followed
every 3 months for survival after disease progression.
PROJECTED ACCRUAL: This study will accrue 20-40 patients in approximately 2 years.
Interventional
Primary Purpose: Treatment
George Wilding, MD
Study Chair
University of Wisconsin, Madison
United States: Federal Government
CDR0000066113
NCT00003238
February 1998
Name | Location |
---|---|
University of Wisconsin Comprehensive Cancer Center | Madison, Wisconsin 53792 |
Gundersen Lutheran Medical Center | La Crosse, Wisconsin 54601 |
Leonard C. Ferguson Cancer Center | Freeport, Illinois 61032 |
Green Bay Oncology, Ltd. | Green Bay, Wisconsin 54307-3453 |
Mercy Health System | Janesville, Wisconsin 53545 |
Meriter Hospital | Madison, Wisconsin 53715 |
Sinai Samaritan Medical Center - Milwaukee | Milwaukee, Wisconsin 53201-0342 |
North Central Oncology Associates, S.C. | Wausau, Wisconsin 54401 |